Bank of America
AUPH icon

Bank of America’s Aurinia Pharmaceuticals AUPH Stock Holding History

Bank of America’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.51M Buy
371,781
+4,145
+1% +$60.6K ﹤0.01% 3391
2025
Q4 		$5.86M Sell
367,636
-153,727
-29% -$2.18M ﹤0.01% 3261
2025
Q3 		$5.76M Buy
521,363
+50,572
+11% +$552K ﹤0.01% 3853
2025
Q2 		$3.99M Buy
470,791
+73,620
+19% +$590K ﹤0.01% 4126
2025
Q1 		$3.19M Buy
397,171
+333,196
+521% +$2.7M ﹤0.01% 4255
2024
Q4 		$574K Sell
63,975
-110,715
-63% -$903K ﹤0.01% 5433
2024
Q3 		$1.28M Buy
174,690
+22,316
+15% +$138K ﹤0.01% 4893
2024
Q2 		$870K Buy
152,374
+35,969
+31% +$189K ﹤0.01% 4986
2024
Q1 		$583K Buy
116,405
+46,991
+68% +$319K ﹤0.01% 5260
2023
Q4 		$624K Sell
69,414
-14,769
-18% -$122K ﹤0.01% 5334
2023
Q3 		$654K Buy
84,183
+20,833
+33% +$204K ﹤0.01% 5127
2023
Q2 		$613K Sell
63,350
-39,955
-39% -$415K ﹤0.01% 5128
2023
Q1 		$1.13M Sell
103,305
-305,421
-75% -$2.69M ﹤0.01% 4810
2022
Q4 		$1.77M Buy
408,726
+149,509
+58% +$868K ﹤0.01% 4363
2022
Q3 		$1.95M Buy
259,217
+132,083
+104% +$1.14M ﹤0.01% 4299
2022
Q2 		$1.28M Buy
127,134
+72,162
+131% +$807K ﹤0.01% 4685
2022
Q1 		$680K Sell
54,972
-7,230
-12% -$112K ﹤0.01% 5580
2021
Q4 		$1.42M Buy
62,202
+18,257
+42% +$433K ﹤0.01% 4906
2021
Q3 		$973K Sell
43,945
-13,617
-24% -$216K ﹤0.01% 5106
2021
Q2 		$746K Sell
57,562
-13,522
-19% -$172K ﹤0.01% 5133
2021
Q1 		$923K Sell
71,084
-31,054
-30% -$451K ﹤0.01% 4895
2020
Q4 		$1.41M Buy
102,138
+73,838
+261% +$1.07M ﹤0.01% 4232
2020
Q3 		$418K Buy
28,300
+8,617
+44% +$125K ﹤0.01% 4842
2020
Q2 		$320K Sell
19,683
-1,346
-6% -$21.6K ﹤0.01% 4950
2020
Q1 		$306K Buy
21,029
+11,779
+127% +$208K ﹤0.01% 4838
2019
Q4 		$187K Buy
9,250
+9,119
+6,961% +$84K ﹤0.01% 5674
2019
Q3 		$1K Sell
131
-3,258
-96% -$19.7K ﹤0.01% 7075
2019
Q2 		$23K Sell
3,389
-10,483
-76% -$66.8K ﹤0.01% 6534
2019
Q1 		$89K Sell
13,872
-16,841
-55% -$112K ﹤0.01% 5939
2018
Q4 		$210K Buy
30,713
+30,360
+8,601% +$175K ﹤0.01% 5482
2018
Q3 		$3K Sell
353
-1,829
-84% -$10.3K ﹤0.01% 6930
2018
Q2 		$12K Buy
2,182
+974
+81% +$5.43K ﹤0.01% 6618
2018
Q1 		$6K Sell
1,208
-7,892
-87% -$42.2K ﹤0.01% 6724
2017
Q4 		$42K Buy
9,100
+9,000
+9,000% +$50K ﹤0.01% 6138
2017
Q3 		$1K Sell
100
-200
-67% -$1.26K ﹤0.01% 6908
2017
Q2 		$2K Sell
300
-1,636
-85% -$11K ﹤0.01% 6733
2017
Q1 		$14K Buy
1,936
+1,836
+1,836% +$8.48K ﹤0.01% 6435
2016
Q4 		$0 Buy
+100
New +$322 ﹤0.01% 7025
2016
Q2 		– Sell
-1,000
Closed -$3K – 7112
2016
Q1 		$3K Buy
+1,000
New +$2.42K ﹤0.01% 6694
2015
Q3 		– Sell
-400
Closed -$1K – 7193
2015
Q2 		$1K Buy
+400
New +$1.48K ﹤0.01% 7111

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America's AUPH Position: Q1 2026 in Review

Bank of America increased its Aurinia Pharmaceuticals (AUPH) stake by 1.1% in Q1 2026, buying an estimated $60.6K and bringing the position to 371,781 shares worth $5.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3391.

Bank of America first reported a position in AUPH in Q2 2015 and has held it in 40 quarters since. The position peaked at $5.86M in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Bank of America held 371,781 shares of Aurinia Pharmaceuticals worth $5.51M as of Q1 2026.
  • Bank of America bought 4,145 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $60.6K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3391 holding.
  • Bank of America first reported a position in Aurinia Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
  • Bank of America's Aurinia Pharmaceuticals position peaked at $5.86M in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.